| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/1999 | CA2241431A1 Novel spoiiie |
| 02/26/1999 | CA2241410A1 Pth |
| 02/25/1999 | WO1999009214A1 Antisense oligonucleotide compositions and methods for the modulation of jnk proteins |
| 02/25/1999 | WO1999009162A2 Delayed progression to aids by a missense allele of the ccr2 gene |
| 02/25/1999 | WO1999009156A2 Protease-related protein |
| 02/25/1999 | WO1999009154A2 Novel hiv-specific synthetic oligonucleotides and methods of their use |
| 02/25/1999 | WO1999009152A1 Human frezzled-like protein |
| 02/25/1999 | WO1999009063A1 Interleukin-18 binding proteins, their preparation and use |
| 02/25/1999 | WO1999009054A2 Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders |
| 02/25/1999 | WO1999009049A1 Hypoxia-regulated genes |
| 02/25/1999 | WO1999009046A1 Hypoxia-regulated genes |
| 02/25/1999 | WO1999009045A1 Antisense and antigene therapeutics with improved binding properties and methods for their use |
| 02/25/1999 | WO1999009032A1 Carbapenems with naphthosultam derivative linked via methylene |
| 02/25/1999 | WO1999009031A1 Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the dna polymerase of hepatitis b virus (hbv) |
| 02/25/1999 | WO1999009030A1 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation |
| 02/25/1999 | WO1999009029A1 PYRROLO[3,2-c]QUINOLINE DERIVATIVES CONTAINING HALOALKOXY GROUP AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF |
| 02/25/1999 | WO1999009027A1 (hetero)aryl-sulfonamide derivatives, their preparation and their use as factor xa inhibitors |
| 02/25/1999 | WO1999009025A2 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor |
| 02/25/1999 | WO1999009024A1 Phenyl urea and phenyl thiourea derivatives as hfgan72 antagonists |
| 02/25/1999 | WO1999009022A1 Furansulfonic acid derivatives and pharmaceutical compositions containing the same |
| 02/25/1999 | WO1999009017A1 Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use |
| 02/25/1999 | WO1999009016A1 Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
| 02/25/1999 | WO1999009015A1 2-{3-[4-(2-t-butyl-6- trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol-fumarate |
| 02/25/1999 | WO1999009014A1 Hiv nuclear localization inhibitors |
| 02/25/1999 | WO1999009011A1 Carbostyril derivatives for inhibiting skin erythema and/or skin pigmentation |
| 02/25/1999 | WO1999009010A1 Crystalline 10,10-bis((2-fluoro-4-pyridinyl)methyl)-9(10h)-anthracenone and an improved process for preparing the same |
| 02/25/1999 | WO1999009006A1 SYNTHESIS OF CLASTO-LACTACYSTIN β-LACTONE AND ANALOGS THEREOF |
| 02/25/1999 | WO1999009005A1 Hiv matrix protein tyrosine position 29 pocket binders |
| 02/25/1999 | WO1999009003A1 3-aryl-succinamido-hydroxamic acids, methods for producing said acids and medicaments containing the same |
| 02/25/1999 | WO1999008994A1 Anti-cancer compounds |
| 02/25/1999 | WO1999008992A1 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| 02/25/1999 | WO1999008987A1 Cyclohexenone long-chain alcohol and medicament containing same |
| 02/25/1999 | WO1999008729A1 Loading and release of water-insoluble drugs |
| 02/25/1999 | WO1999008718A2 Bioresorbable compositions for implantable prostheses |
| 02/25/1999 | WO1999008711A1 Lipid-polyamide conjugates and compositions for nucleic acid delivery |
| 02/25/1999 | WO1999008697A1 Treatment of congestive heart failure with growth hormone secretagogues |
| 02/25/1999 | WO1999008690A1 Method of enhancing bioavailability of fexofenadine and its derivatives |
| 02/25/1999 | WO1999008687A1 13-deoxyanthracycline derivatives and processes for preparing them |
| 02/25/1999 | WO1999008686A1 Use of uridine to counter 5-fluorouracil toxicity |
| 02/25/1999 | WO1999008685A1 Phosphono-carboxylate compounds for treating amyloidosis |
| 02/25/1999 | WO1999008684A2 Solutions containing azasteroids |
| 02/25/1999 | WO1999008682A1 A method of preventing or treating estrogen-dependent diseases and disorders |
| 02/25/1999 | WO1999008680A1 Method of using selective parp inhibitors to prevent or treat neurotoxicity |
| 02/25/1999 | WO1999008678A1 Heterocyclic vinylethers against neurological disorders |
| 02/25/1999 | WO1999008677A1 METHODS FOR INHIBITING DETRIMENTAL SIDE-EFFECTS DUE TO GnRH OR GnRH AGONIST ADMINISTRATION |
| 02/25/1999 | WO1999008676A1 Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents |
| 02/25/1999 | WO1999008675A1 Remedies for irritable bowel syndrome |
| 02/25/1999 | WO1999008674A1 New uses of tea pigment |
| 02/25/1999 | WO1999008673A1 Enantiomers of 4-[[(cyanoimino)- [(1,2,2-trimethylpropyl) amino]methyl]amino] benzonitrile |
| 02/25/1999 | WO1999008672A1 Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity |
| 02/25/1999 | WO1999008671A1 Gaba analogs to prevent and treat gastrointestinal damage |
| 02/25/1999 | WO1999008670A1 Gaba analogs to prevent and treat gastrointestinal damage |
| 02/25/1999 | WO1999008669A1 Agmatine as a treatment for neuropathic pain |
| 02/25/1999 | WO1999008668A2 Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
| 02/25/1999 | WO1999008667A2 Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants |
| 02/25/1999 | WO1999008666A2 Pharmaceutical composition comprising an azateroid |
| 02/25/1999 | WO1999008663A1 Parenteral pimaricin as treatment of systemic infections |
| 02/25/1999 | WO1999008661A1 Controlled release dosage forms containing water soluble drugs |
| 02/25/1999 | WO1999008660A1 Solid pharmaceutical dosage forms in form of a particulate dispersion |
| 02/25/1999 | WO1999008658A1 Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
| 02/25/1999 | WO1999008657A2 Self-binding shearform compositions |
| 02/25/1999 | WO1999008656A1 Antacid composition |
| 02/25/1999 | WO1999008654A1 USE OF 17-α-ESTRADIOL FOR THE TREATMENT OF AGED OR SUNDAMAGED SKIN AND/OR SKIN ATROPHY |
| 02/25/1999 | WO1999008651A1 Skin care compositions and use |
| 02/25/1999 | WO1999008536A1 Antiviral agent |
| 02/25/1999 | WO1999008526A1 Methods for inhibiting temporomandibular disorders |
| 02/25/1999 | WO1999008525A1 Methods for lowering platelet counts |
| 02/25/1999 | WO1999008524A1 Methods for preventing headaches |
| 02/25/1999 | WO1999008523A1 Methods for inhibiting fibrous inflammatory disease and riedel's thyroiditis |
| 02/25/1999 | WO1999008521A1 Treatment or prophylaxis of retinal pathology and spinal cord injury |
| 02/25/1999 | WO1999008519A1 Polyamine treatment of neurological disorders |
| 02/25/1999 | WO1999008514A1 Compositions containing polyethylene glycol and uses thereof |
| 02/25/1999 | WO1999008500A2 New crystalline form of omeprazole |
| 02/25/1999 | WO1998052915A3 Leukotriene b4 derivatives, in particular oximo-ltb4 antagonists |
| 02/25/1999 | WO1998052555A3 Use of n-acetyl-l-cysteine for treating male infertility |
| 02/25/1999 | WO1998047866A3 Arylsecocholadiene derivatives |
| 02/25/1999 | WO1998046243A3 Pharmaceutical compositions having appetite suppressant activity |
| 02/25/1999 | WO1998045259A3 Polyaromatic antiviral compositions |
| 02/25/1999 | WO1998042659A3 Aryl- or heteroarylsulfonamide substituted hydroxamic acid derivates, process for their preparation and their use as pharmaceuticals |
| 02/25/1999 | WO1998032017A3 Modulators of insulin receptor activity |
| 02/25/1999 | WO1998005678A3 Novel cationic amphiphilic lipids for liposomal gene transfer |
| 02/25/1999 | DE19837386A1 New CCR-3 antagonist piperazine derivatives and analogues |
| 02/25/1999 | DE19833750A1 New thiazolyl-alkadienol and -epoxide derivatives |
| 02/25/1999 | DE19737436A1 New PDE IV inhibitors to suppress cytokine activated monocyte extra-vasation |
| 02/25/1999 | DE19736539A1 Use of cycloalkyl-substituted phosphonic acid ester(s) for treating cognitive and affective disorders |
| 02/25/1999 | CA2363810A1 New form of omeprazole |
| 02/25/1999 | CA2301921A1 Compositions containing polyethylene glycol and uses thereof |
| 02/25/1999 | CA2301806A1 Methods for lowering platelet counts |
| 02/25/1999 | CA2301297A1 2-{3-[4-(2-t-butyl-6- trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol-fumarate |
| 02/25/1999 | CA2301292A1 Antacid composition |
| 02/25/1999 | CA2301228A1 Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
| 02/25/1999 | CA2301227A1 Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use |
| 02/25/1999 | CA2301139A1 Antisense oligonucleotide compositions and methods for the modulation of jnk proteins |
| 02/25/1999 | CA2301074A1 Crystalline 10,10-bis((2-fluoro-4-pyridinyl)methyl)-9(10h)-anthracenone and an improved process for preparing the same |
| 02/25/1999 | CA2301054A1 Synthesis of clasto-lactacystin .beta.-lactone and analogs thereof |
| 02/25/1999 | CA2301016A1 Use of 17-.alpha.-estradiol for the treatment of aged or sundamaged ski n and/or skin atrophy |
| 02/25/1999 | CA2300995A1 Methods for inhibiting detrimental side-effects due to gnrh or gnrh agonist administration |
| 02/25/1999 | CA2300938A1 Antisense and antigene therapeutics with improved binding properties and methods for their use |
| 02/25/1999 | CA2300912A1 3-aryl-succinamido-hydroxamic acids, methods for producing said acids and medicaments containing the same |
| 02/25/1999 | CA2300848A1 Treatment of congestive heart failure with growth hormone secretagogues |